Tag: liver cancer
Society of Interventional Oncology announces third European site approved in ACCLAIM...
The Society of Interventional Oncology (SIO) announces the European Institute of Oncology (IEO) in Milan, Italy, as the next European site approved for enrolment...
First UK NHS hospital to use AI-enhanced treatment overcomes “Achilles’ heel”...
In the final months of 2023, the Addenbrooke Hospital in Cambridge, UK, were reported as the first UK National Health Service (NHS) facility to...
Delcath Systems announces additional funding for Hepzato Kit FDA approval
Delcath Systems, an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, has announced that it raised approximately...
PAIRS 2023: What the BCLC guidelines have omitted
Sarah White (Medical College of Wisconsin, Milwaukee, USA) opened the liver interventional oncology (IO) session at the Pan Arab Interventional Radiology Society (PAIRS) annual...
Delcath Systems announces new drug application resubmission for Hepzato Kit
Delcath Systems has announced it has submitted a new drug application (NDA) resubmission to the US Food and Drug Administration (FDA) for the Hepzato...
HKUMed discovers new trimodality therapy for locally advanced liver cancer
A phase II clinical study on a trimodality therapy (START-FIT), conducted by the Departments of Surgery and Clinical Oncology, School of Clinical Medicine, University...
Lyon hospital group adopts Epione robotic ablation platform
Hospices Civils de Lyon (HCL; Lyon, France) has acquired Epione, the robotic platform developed by Quantum Surgical (QS) that is designed to enable minimally...
Authors receive accolade of ‘Abstract of the Year’ at SIR 2022
At the Society of Interventional Radiology (SIR) 2022 Annual Meeting (11-16 June, Boston, USA), four of the abstracts submitted were declared ‘Abstract of the...
TriSalus presents preclinical data on proprietary infusion technology at SIR 2022
TriSalus’ clinical leadership team presented new preclinical data at the Society of Interventional Radiology (SIR) 2022 Annual Scientific Meeting (11–16 June, Boston, USA). The...
Holmium-166 SIRT demonstrates safety and efficacy in the treatment of HCC
University Medical Center Utrecht (Utrecht, Netherlands) recently published the latest results from the HEPAR Primary study, which evaluated the safety and efficacy of Holmium-166...
Phase III RCTs needed to prove radiofrequency ablation is effective against...
Interventional radiologists must become involved in the multidisciplinary development of phase III randomised controlled trials (RCTs) to further assess the role of radiofrequency ablation...
Targeted immunotherapy treatment shows promise for treating for advanced liver cancer
Advanced stage liver tumours may be safely treated through image-guided injections of an immunotherapy approved for melanoma, according to phase 1 data presented at...
Surefire Medical appoints Mary T Szela CEO and president
Szela brings nearly 30 years of progressive leadership experience to Surefire building global billion-dollar brands, advancing pipeline products in the biotechnology, medical products, and...
Vast majority of patients prefer radial access for embolization therapies in...
“While both radial and femoral accesses are safe and effective for transarterial liver embolization, it is clear that the patients prefer radial access,” said Marcelo Guimaraes, Charleston, USA, who was presenting on the...
